

DAFTAR PUSTAKA

- Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G. and von Deimling, A., 2015. Glioblastoma: pathology, molecular mechanisms and markers. *Acta neuropathologica*, 129(6), pp.829-848.
- Alkhaibary, A., Alassiri, A.H., AlSufiani, F. and Alharbi, M.A., 2018. Ki-67 labeling index in glioblastoma; does it really matter?. *Hematology/oncology and stem cell therapy*.
- Byreddy, V. R., Sreelakshmi, I., Arasi, E. N., 2018. Role of Ki 67 Immunostaining as an Adjunct to Differentiate Low Grade and High Grade Glioma. 17(7), pp. 11–17. doi: 10.9790/0853-1707161117.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 68(6), pp.394-424.
- Cai, J., Zhang, C., Zhang, W., Wang, G., Yao, K., Wang, Z., Li, G., Qian, Z., Li, Y., Jiang, T. and Jiang, C., 2016. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. *Oncoscience*, 3(7-8), p.258.
- Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. *Asian Pac J Cancer Prev*. 2015;16(2):411-20.



- Cohen, A.L., Holmen, S.L., Colman, H., 2013. IDH1 and IDH2 Mutations in Gliomas. *Current Neurology and Neuroscience Reports* 13. doi:10.1007/s11910-013-0345-4.
- Collins, V.P., Jones, D.T. and Giannini, C., 2015. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. *Acta neuropathologica*, 129(6), pp.775-788.
- Dimitrov, L., Hong, C.S., Yang, C., Zhuang, Z., Heiss, J.D., 2015. New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. *International Journal of Medical Sciences* 12, 201–213. doi:10.7150/ijms.11047.
- Dowsett, M., Nielsen, T.O., A'Hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., Ellis, M., Henry, N.L., Hugh, J.C., Lively, T. and McShane, L., 2011. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *Journal of the National Cancer Institute*, 103(22), pp.1656-1664.
- Dunbar, E. and Yachnis, A.T., 2010. Glioma diagnosis: immunohistochemistry and beyond. *Advances in anatomic pathology*, 17(3), pp.187-201.
- Ellison, D.W., Kocak, M., Figarella-Branger, D., Felice, G., Catherine, G., Pietsch, T., Frappaz, D., Massimino, M., Grill, J., Boyett, J.M. and Grundy, R.G., 2011. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. *Journal of negative results in biomedicine*, 10(1), p.7.



- Frosch, M.P., Anthony, D.C., Girolami, U.D., 2012. Pathologic Basis of Disease 9th Edition: The Central Nervous System 28,1251-1318.
- Gown, A.M., 2016. Diagnostic Immunohistochemistry: What can go wrong and how to prevent it. Arch Pathol Lab Med 180; 893-898.
- Habberstad, A.H., Gulati, S. and Torp, S.H., 2011. Evaluation of the proliferation markers Ki-67/MIB-1, mitotin, survivin, pHH3, and DNA topoisomerase II α in human anaplastic astrocytomas-an immunohistochemical study. Diagnostic pathology, 6(1), p.43.
- Hardee, M.E. and Zagzag, D., 2012. Mechanisms of glioma-associated neovascularization. The American journal of pathology, 181(4), pp.1126-1141.
- Haynes, H.R., Camelo-Piragua, S. and Kurian, K.M., 2014. Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Frontiers in oncology, 4, p.47.
- Hsu, C.Y., Ho, D.M.T., Yang, C.F. and Chiang, H., 2003. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Modern pathology, 16(9), p.951
- Jang, M.H., Kim, H.J., Chung, Y.R., Lee, Y. and Park, S.Y., 2017. A comparison of Ki-67 counting methods in luminal breast cancer: the average method vs. the hot spot method. PloS one, 12(2), p.e0172031.
- Johannessen, A.L. and Torp, S.H., 2006. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathology & Oncology Research, 12(3), p.143.



- Kanyilmaz, G., Önder, H., Aktan, M., Mehmet, K.O.Ç., Hüseyin, B.O.R.A., Karahacioğlu, E., Erkal, H.Ş. and Erkal, E.Y., 2018. Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors. *Turkish Journal Of Oncology*, 33(2).
- Leung, S.C., Nielsen, T.O., Zabaglo, L., Arun, I., Badve, S.S., Bane, A.L., Bartlett, J.M., Borgquist, S., Chang, M.C., Dodson, A. and Enos, R.A., 2016. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. *NPJ Breast Cancer*, 2, p.16014.
- Lindboe, C.F. and Torp, S.H., 2002. Comparison of Ki-67 equivalent antibodies. *Journal of clinical pathology*, 55(6), pp.467-471.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., 2007. WHO Classification of Tumors of the central nervous system 4, 8-80.
- Louis, D.N., Perry, A., Burger, P., Ellison, D.W., Reifenberger, G., von Deimling, A., Aldape, K., Brat, D., Collins, V.P., Eberhart, C. and Figarella-Branger, D., 2014. International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. *Brain pathology*, 24(5), pp.429-435.
- Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica* 131, 803–820. doi:10.1007/s00401-016-1545-1.



Luporsi, E., André, F., Spyrtatos, F., Martin, P.M., Jacquemier, J., Penault-Llorca, F., Tubiana-Mathieu, N., Sigal-Zafrani, B., Arnould, L., Gompel, A. and Egele, C., 2012. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. *Breast cancer research and treatment*, 132(3), pp.895-915.

Magalhães, A. C. and Rivera, C. (2014) 'Superior performance of decloaking chamber-based heat-induced epitope retrieval method improves the quantification of Olig2 cells in paraffin-embedded section of embryonic mouse brain', *Journal of Neuroscience Methods*. Elsevier B.V., 235, pp. 226–233. doi: 10.1016/j.jneumeth.2014.06.032.

Menon, A., 2017, *Biomarkers in Gliomas*, <https://www.slideshare.net/ashutoshmukherji/biomarkers-in-gliomas>, & December 2017, 18 July 2019.

Molenaar, R.J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J.W.M., Boots-Sprenger, S.H.E., Wesseling, P., Hulsebos, T.J.M., Troost, D., van Tilborg, A.A., Leenstra, S., Vandertop, W.P., Bardelli, A., van Noorden, C.J.F., Bleeker, F.E., 2014. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. *Neuro-Oncology* 16, 1263–1273. doi:10.1093/neuonc/nou005.

Nuovo, G., 2016. False-Positive Results in Diagnostic Immunohistochemistry are Related to Horseradish Peroxidase Conjugates in Commercially Available Assays. *Annals of Diagnostic Pathology*, 25; 54-59.



- Ostrom, Q.T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., Sloan, J.S.B.,
2018. CBTRUS Statistical Report: Primary Brain and Other Central
Nervous System Tumors Diagnosed in the United States in 2011-2015.
Neuro-Oncology 20 (S4), 1-86.
- Ohgaki, H. and Kleihues, P., 2007. Genetic pathways to primary and secondary
glioblastoma. *The American journal of pathology*, 170(5), pp.1445-1453.
- Pathmanathan, N. and Balleine, R.L., 2013. Ki67 and proliferation in breast cancer.
Journal of clinical pathology, 66(6), pp.512-516.
- Pelosi, G. et al. (2014) 'Ki-67 antigen in lung neuroendocrine tumors: Unraveling
a role in clinical practice', *Journal of Thoracic Oncology*. doi:
10.1097/JTO.0000000000000092.
- Perry, A. and Wesseling, P., 2016. Histologic classification of gliomas. In
Handbook of clinical neurology (Vol. 134, pp. 71-95). Elsevier.
- Preusser, M., Budka, H., Rössler, K. and Hainfellner, J.A., 2007. OLIG2 is a useful
immunohistochemical marker in differential diagnosis of clear cell
primary CNS neoplasms. *Histopathology*, 50(3), pp.365-370.
- Rasmussen, B.K., Hansen, S., Laursen, R.J., Kostejanetz, M., Schultz, H., Norgard,
B.M., Guldberg, R., Gradel, K.O., 2017. Epidemiology of Glioma:
Clinical Characteristics, Symptoms, and Predictors of Glioma Patients
Grade I-IV in the Danish Neuro-Oncology Registry. *J Neurooncol*. doi:
10.1007/s11060-017-2607-5.



- Shaffrey, M.E., Farace, E., Schiff, D., Lerner, J.M., Mut, M. and Lopes, M.B.S., 2005. The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. *Journal of neurosurgery*, 102(6), pp.1033-1039.
- Sharma, M.C., Ralte, A.M., Gaekwad, S., Santosh, V., Shankar, S.K. and Sarkar, C., 2004. Subependymal giant cell astrocytoma—a clinicopathological study of 23 cases with special emphasis on histogenesis. *Pathology Oncology Research*, 10(4), pp.219-224.
- Shi, S. R., Shi, Y. and Taylor, C. R. (2011) 'Antigen retrieval immunohistochemistry: Review and future prospects in research and diagnosis over two decades', *Journal of Histochemistry and Cytochemistry*, 59(1), pp. 13–32. doi: 10.1369/jhc.2010.957191.
- Skjulsvik, A.J., Mørk, J.N., Torp, M.O. and Torp, S.H., 2014. Ki-67/MIB-1 immunostaining in a cohort of human gliomas. *International journal of clinical and experimental pathology*, 7(12), p.8905.
- Stupp, R., Brada, M., Van Den Bent, M.J., Tonn, J.C., Pentheroudakis, G., 2014. High grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annal of Oncology* 25; iii95-iii101.
- Sturm, D., Pfister, S.M. and Jones, D.T., 2017. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. *Journal of Clinical Oncology*, 35(21), pp.2370-2377.
- Tavares, C.B., Gomes, F.D.C.S.A., Sousa, E.B. and de Oliveira Brito, J.N.P., 2016. Expression of Ki-67 in Low-Grade and High-Grade Astrocytomas. *JBNC-Jornal Brasileiro De Neurocirurgia*, 27(3), pp.225-230.



- Thotakura, M., Tirumalasetti, N. and Krishna, R., 2014. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. *Journal of cancer research and therapeutics*, 10(3), p.641.
- Trembath, D., Miller, C.R. and Perry, A., 2008. Gray zones in brain tumor classification: evolving concepts. *Advances in anatomic pathology*, 15(5), pp.287-297.
- Wesseling, P. and Capper, D., 2018. WHO 2016 classification of gliomas. *Neuropathology and applied neurobiology*, 44(2), pp.139-150.
- Wu, J., Armstrong, T.S. and Gilbert, M.R., 2016. Biology and management of ependymomas. *Neuro-oncology*, 18(7), pp.902-913.
- Yao, Y., Mack, S.C. and Taylor, M.D., 2011. Molecular genetics of ependymoma. *Chinese journal of cancer*, 30(10), p.669.
- Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., Gu, A., 2013. IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis. *PLoS ONE* 8, e68782. doi:10.1371/journal.pone.0068782.